Glenmark Life Sciences Ltd. Stock Analysis GLS.NS

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 2,014 full-time employees. The company went IPO on 2021-08-06. The firm is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). The company also develops APIs in the therapeutic areas such as anti-fungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. The company has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of approximately 1198 KL.